In a patient with congestive heart failure and worsening pulmonary congestion who is already on sacubitril/valsartan (Entresto), carvedilol, spironolactone, and empagliflozin (Jardiance), is adding digoxin (Lanoxin) helpful?

Adding Digoxin to Optimized GDMT in Heart Failure with Worsening Pulmonary Congestion

Digoxin may be considered as an additional therapy in this patient with persistent pulmonary congestion despite optimal guideline-directed medical therapy (GDMT), though its benefit is modest and primarily limited to reducing heart failure hospitalizations rather than improving mortality. 1

Current Guideline Recommendations

The 2022 AHA/ACC/HFSA guidelines assign digoxin a Class 2b recommendation (Level B-R evidence), meaning it "might be considered" in patients with symptomatic HFrEF despite GDMT or in those unable to tolerate GDMT 1. This is a relatively weak recommendation that reflects:

• No mortality benefit: The landmark DIG trial showed digoxin had no effect on death rates 1
• Modest hospitalization reduction: The primary benefit is a moderate decrease in heart failure hospitalizations 1
• Uncertain benefit with modern GDMT: Most digoxin trials preceded current therapies like sacubitril/valsartan and SGLT2 inhibitors, making its incremental benefit unclear when added to your patient's already optimized regimen 1

Key Considerations Before Adding Digoxin

When Digoxin May Be Reasonable:

• Persistent symptoms despite maximized doses of Entresto, carvedilol, spironolactone, and Jardiance
• Sinus rhythm with elevated heart rate (though ivabradine would be preferred if HR ≥70 bpm) 1
• Atrial fibrillation requiring rate control (digoxin becomes more useful here) 2
• Severe heart failure with cardiomegaly and third heart sound 2

Critical Safety Concerns from FDA Labeling:

The Lanoxin label highlights several important contraindications and warnings 3:

• Avoid if significant sinus or AV block unless pacemaker present
• Use cautiously with carvedilol: Both drugs depress AV nodal function, increasing risk of bradycardia and heart block 3
• Spironolactone interaction: Increases digoxin levels and toxicity risk 3
• Renal function monitoring: Essential given your patient is on multiple nephrotoxic agents

Dosing and Monitoring:

If you proceed with digoxin 1, 3:

• Start low: 0.125 mg daily (or every other day if age >70, impaired renal function, or low body weight)
• Target serum level: 0.5-0.9 ng/mL (levels >1.2 ng/mL associated with increased mortality)
• Monitor electrolytes closely: Hypokalemia, hypomagnesemia, and hypercalcemia predispose to toxicity—particularly concerning given spironolactone use
• No loading dose needed in chronic heart failure

Alternative Approaches to Consider First

Before adding digoxin, ensure you've optimized:

1. Diuretic therapy: Increase loop diuretic dose or add thiazide for worsening pulmonary congestion
2. Carvedilol dose: Confirm patient is on maximum tolerated beta-blocker dose
3. Ivabradine: If patient is in sinus rhythm with HR ≥70 bpm, this has stronger evidence (Class 2a) than digoxin 1
4. Volume status assessment: Ensure congestion isn't simply undertreated with diuretics

Clinical Bottom Line

Given the modest and uncertain benefit of digoxin when added to modern quadruple therapy (ARNI, beta-blocker, MRA, SGLT2i), prioritize aggressive diuretic optimization for the acute pulmonary congestion first. If symptoms persist despite maximized GDMT and adequate decongestion, digoxin becomes a reasonable adjunctive option, but maintain heightened vigilance for drug interactions (particularly with spironolactone and carvedilol) and monitor for toxicity closely 1, 3.

The evidence supporting digoxin is substantially weaker than for your patient's current medications, all of which have demonstrated mortality benefits that digoxin lacks 1.